The role of ABC transporters in anticancer drug transport

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Turkish Journal of Biology

• Publication date

  2014-12-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3906/BIY-1407-3
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer drug resistance: an evolving paradigm

  2013influential reference
• ABC transporters in cancer: more than just drug efflux pumps

  2010influential reference
• Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs

  2009influential reference
• ABC Transporters, Drug Resistance, and Cancer Stem Cells

  2009cited by this paper
• Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.

  2008cited by this paper
• Expression profile of early lung adenocarcinoma: identification of MRP3 as a molecular marker for early progression

  2008influential reference
• Expression of multidrug resistance‐associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin

  2008influential reference
• Neuroblastoma

  2007influential reference
• Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor.

  2007influential reference
• The ABCA subfamily—gene and protein structures, functions and associated hereditary diseases

  2007influential reference
• Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.

  2006influential reference
• Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.

  2006influential reference
• ABCA3 as a Possible Cause of Drug Resistance in Childhood Acute Myeloid Leukemia

  2006influential reference
• ATP‐binding cassette superfamily transporter gene expression in human soft tissue sarcomas

  2005influential reference
• The genetics of ATP-binding cassette transporters.

  2005cited by this paper
• A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.

  2005cited by this paper
• Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma

  2005influential reference
• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

  2004cited by this paper
• Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

  2004influential reference
• Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells.

  2004influential reference
• Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979

  2003cited by this paper
• Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice.

  2003influential reference
• Overcoming Multidrug Resistance in Cancer: An Update on the Clinical Strategy of Inhibiting P-Glycoprotein

  2003influential reference
• The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1a suppresses polyp formation in ApcMin/+ mice

  2003influential reference
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002influential reference
• In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II

  2002cited by this paper
• MDR1 inhibition: less resistance or less relevance?

  2002cited by this paper
• The human ATP-binding cassette (ABC) transporter superfamily.

  2001cited by this paper
• Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.

  2001cited by this paper
• Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

  2001influential reference
• P-glycoprotein and MRP1 expression in axillary lymph node metastases of breast cancer patients.

  2001influential reference
• Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

  2001cited by this paper
• Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.

  2000influential reference
• Development of Multidrug-Resistance Convertors: Sense or Nonsense?

  2000cited by this paper
• Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.

  2000cited by this paper
• Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives.

  1999cited by this paper
• Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin.

  1999influential reference
• Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

  1999cited by this paper
• Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

  1999influential reference
• Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.

  1997cited by this paper
• Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

  1997cited by this paper
• Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

  1996cited by this paper
• Clinical trials of P-glycoprotein reversal in solid tumours.

  1996cited by this paper
• Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?

  1996cited by this paper
• Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

  1994cited by this paper
• Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype

  1992cited by this paper
• Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

  1991cited by this paper
• Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected].

  1991cited by this paper
• Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis.

  1991influential reference

• The Role of Exosomes as a Key Factor of Cytostatic Resistance in Cancer: Mechanisms of Action, Potential Biomarkers, and Possible Exosome-Based Therapies

  2025cites this paper
• The role of diet and nutraceuticals in the amelioration of multidrug resistance amongst cancer patients

  2025cites this paper
• Therapeutic strategies to overcome taxane resistance in cancer.

  2021cites this paper
• MicroRNAs in Pancreatic Cancer and Chemoresistance

  2021cites this paper
• Mechanisms of Multidrug Resistance in Cancer Chemotherapy

  2020cites this paper
• The Problem of Drug Resistance in Cancer Chemotherapy

  2020cites this paper
• The effect of ATP-binding cassette (ABC) transporters in human cancers

  2019cites this paper
• Solid lipid nanoparticles in reversing the acquired tamoxifen-resistance

  2017cites this paper
• Hematoporphyrin and doxorubicin co-loaded nanomicelles for the reversal of drug resistance in human breast cancer cells by combining sonodynamic therapy and chemotherapy

  2016cites this paper
• Development of therapeutic proteins: advances and challenges

  2015cites this paper
• ABC transporters in anticancer drug transport ? Lessons for Therapy,Drug Development and Delivery Systems

  2015cites this paper